Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Assets: 2016-2024

Historic Current Assets for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $482.3 million.

  • Collegium Pharmaceutical's Current Assets rose 38.32% to $613.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $613.9 million, marking a year-over-year increase of 38.32%. This contributed to the annual value of $482.3 million for FY2024, which is 10.29% down from last year.
  • As of FY2024, Collegium Pharmaceutical's Current Assets stood at $482.3 million, which was down 10.29% from $537.6 million recorded in FY2023.
  • Over the past 5 years, Collegium Pharmaceutical's Current Assets peaked at $537.6 million during FY2023, and registered a low of $277.9 million during FY2020.
  • In the last 3 years, Collegium Pharmaceutical's Current Assets had a median value of $482.3 million in 2024 and averaged $479.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 33.10% in 2022, then dropped by 10.29% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Current Assets (Yearly) stood at $277.9 million in 2020, then climbed by 13.55% to $315.5 million in 2021, then soared by 33.10% to $420.0 million in 2022, then grew by 28.00% to $537.6 million in 2023, then declined by 10.29% to $482.3 million in 2024.